Integra LifeSciences (NASDAQ:IART) Stock Price Up 9.1% – Should You Buy?

Integra LifeSciences Holdings Corporation (NASDAQ:IART)’s stock price shot up 9.1% on Monday. The company traded as high as $13.97 and last traded at $13.91. 566,782 shares were traded during trading, a decline of 39% from the average daily volume of 922,816 shares. The stock had previously closed at $12.75.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the company. Zacks Research cut Integra LifeSciences from a “hold” rating to a “strong sell” rating in a report on Monday, October 26th. Citigroup reiterated an “outperform” rating on shares of Integra LifeSciences in a report on Thursday, October 22nd. Citizens Jmp decreased their price target on Integra LifeSciences from $25.00 to $22.00 and set a “market outperform” rating on the stock in a research report on Thursday, October 22nd. Weiss Ratings raised Integra LifeSciences from a “sell (e+)” rating to a “sell (d+)” rating in a research note on Monday, October 26th. Finally, BMO Capital Markets reiterated a “market perform” rating and issued a $14.00 price objective (down from $15.00) on shares of Integra LifeSciences in a report on Thursday, October 22nd. Two research analysts have rated the stock with a Buy rating, five have given a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat, Integra LifeSciences presently has an average rating of “Reduce” and a consensus price target of $16.12.

Integra LifeSciences Stock Up 7.5%

The company has a market cap of $1.07 billion, a P/E ratio of 80.52, a price-to-earnings-growth ratio of 0.50 and a beta of 1.28. The company has a quick ratio of 2.21, a current ratio of 3.62 and a debt-to-equity ratio of 1.67. The company has a fifty day moving average of $14.83 and a 200 day moving average of $14.08.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings results on Wednesday, October 21st. The life sciences company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.56 by $0.03. Integra LifeSciences had a net margin of 0.79% and a return on equity of 18.63%. The firm had revenue of $411.18 million during the quarter, compared to analyst estimates of $413.16 million. During the same quarter in the prior year, the firm earned ($0.07) EPS. On average, research analysts anticipate that Integra LifeSciences Holdings Corporation will post 2.34 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Integra LifeSciences

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Public Employees Retirement System of Ohio bought a new stake in shares of Integra LifeSciences during the second quarter valued at approximately $82,000. Integrated Wealth Concepts LLC acquired a new position in shares of Integra LifeSciences in the 2nd quarter valued at about $84,000. Sequoia Financial Advisors LLC increased its holdings in Integra LifeSciences by 27.4% in the first quarter. Sequoia Financial Advisors LLC now owns 14,233 shares of the life sciences company’s stock valued at $134,000 after buying an additional 3,059 shares in the last quarter. Amundi raised its stake in shares of Integra LifeSciences by 80.8% during the 1st quarter. Amundi now owns 19,430 shares of the life sciences company’s stock worth $183,000 after buying an additional 8,681 shares during the period. Finally, Corient Private Wealth LP increased its position in shares of Integra LifeSciences by 66.9% during the second quarter. Corient Private Wealth LP now owns 22,749 shares of the life sciences company’s stock worth $409,000 after purchasing an additional 9,120 shares in the last quarter. Hedge funds and other institutional investors own 84.78% of the company’s stock.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation (NASDAQ:IART) is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery, orthopedics and wound care. Its portfolio includes medical devices, surgical instruments and regenerative tissue technologies designed to help healthcare professionals treat complex conditions and support patient recovery.

Integra’s neurosurgical products include dural repair products, cerebrospinal fluid management systems, cranial stabilization devices and specialized surgical instruments.